Post-traumatic stress disorder affects an estimated 3.5 percent of U.S. adults in any given year, with significantly higher prevalence in military veterans, first responders, survivors of childhood abuse, and others who have experienced prolonged or severe trauma. Standard treatments — primarily prolonged exposure therapy and EMDR among psychotherapies, and SSRIs as pharmacological first-line options — leave a substantial portion of patients without adequate relief. We work with many of those patients at Minnesota Ketamine & Wellness Institute, and we approach PTSD care with the conviction that the intersection of anesthesia-level pharmacological expertise and trauma-specialized psychotherapy creates something neither discipline could achieve alone.
How Traumatic Memory Works — and Where Ketamine Fits
Understanding how ketamine may benefit PTSD requires a brief look at how traumatic memory works. When a threat occurs, the brain’s memory consolidation process encodes not just the factual content of the experience but its emotional charge — the fear, helplessness, or horror that accompanied it. This encoded fear memory is stored in ways that remain accessible long after the threat has passed, which is why trauma survivors can be thrown into a physiological threat response by a smell, a sound, or a sensory similarity to the original event. The amygdala, hippocampus, and prefrontal cortex are the central players in this system, and PTSD appears to involve an amygdala that is hyperreactive, a hippocampus that has difficulty contextualizing memories as past, and a prefrontal cortex that cannot reliably suppress the threat response.
Ketamine’s relevance to PTSD begins at the level of fear memory reconsolidation. Research suggests that fear memories, when retrieved, briefly become labile — susceptible to modification before being re-stored. If a patient retrieves a traumatic memory during a period when ketamine has elevated BDNF, promoted synaptogenesis, and temporarily disrupted rigid neural patterns, the re-consolidation of that memory may be less charged, less rigid, less automatic. This is a theoretical model supported by emerging research, not a confirmed mechanism in the clinical sense, and we present it that way. The psychiatric use of IV ketamine for PTSD is off-label — not FDA-approved for this indication — and the evidence base, while promising, remains at earlier stages than the literature on depression. Results vary by individual. To understand more about what ketamine infusions are and how they work, our overview article provides a helpful starting point.
Our Clinical Approach to PTSD
What distinguishes our clinical approach to PTSD is the depth of our multidisciplinary team. Christy Hatcher, MSN, APRN, CRNA provides the pharmacological precision — dosing, monitoring, titration, and safety throughout each ketamine infusion — that patients with complex trauma histories require. But clinical safety in PTSD treatment is not only pharmacological; it is relational and psychological. Patients with histories of trauma need to feel genuinely safe with their care team before they will open to the kind of therapeutic depth that KAP makes possible. Building that safety is the work of our preparation phase, and it is not rushed. We work with trauma survivors on their timeline, not ours.
Our therapists include Certified Clinical Trauma Professionals (CCTPs) and Somatic Psychedelic Facilitators who bring specific training in trauma-informed care and in how to work therapeutically with non-ordinary states. Somatic approaches are particularly relevant for PTSD, where trauma is frequently held in the body as muscle tension, autonomic hyperarousal, collapse, or dissociation. A somatic facilitator can work with what arises in the body during a ketamine session in ways that a purely verbal psychotherapy cannot, potentially supporting the kind of nervous system reorganization that standard talk therapy may not reach. This is not a guarantee of outcome — again, results vary by individual — but it reflects a clinically serious approach to treating the whole person. Learn more about our ketamine-assisted psychotherapy in Minnesota and how this integrated model supports patients through every phase of care.
Veterans and the VA Community Care Network
Veterans are among the populations for whom ketamine has been most actively studied for PTSD. Our institute holds a VA Community Care Network (VCA) contract, which means the VA will refer eligible veterans to us and cover the cost of ketamine infusions through that contract. Veterans do not need to navigate the cost of infusions out of pocket when referred through this pathway — a meaningful distinction given that financial barriers are one of the most common reasons PTSD patients delay or forgo treatment. Veterans interested in this pathway should discuss eligibility with their VA care coordinator, who can initiate the referral process. Our team is familiar with the clinical presentations common to military trauma, including moral injury and combat-related PTSD, and is prepared to receive VA referrals directly.
Addressing the Fear of Retraumatization
One of the barriers we address with PTSD patients is the fear that a ketamine experience will surface traumatic material in a way that overwhelms them. This is a legitimate concern that deserves an honest response. A ketamine session can bring up difficult emotional content, and for trauma survivors, the distinction between therapeutic processing and retraumatization is not always clear in the moment. Our preparation protocol directly addresses this concern: we develop grounding tools, establish safety signals, set intentions collaboratively, and build a clear therapeutic relationship before the first session. Discuss with your provider in advance how your specific trauma history, symptoms, and prior treatment experiences should shape the preparation approach. We do not proceed with a session until both the patient and clinical team feel that adequate preparation is in place.
The second barrier is the sense that PTSD is too severe or too chronic for treatment to help. We hear this frequently, and it reflects the profound demoralization that complex trauma generates over time. Clinical research on ketamine for PTSD has specifically included patients with long-standing, treatment-resistant PTSD — not only recent-onset presentations — and found meaningful responses in a meaningful proportion of participants. The American Society of Ketamine Physicians, Psychotherapists & Practitioners has published guidelines that address PTSD treatment with ketamine, and ongoing research from institutions including the VA system continues to expand the evidence base. None of this constitutes a promise of outcome; we are clear about that. What we offer is a clinically serious, carefully structured program that has helped patients who believed nothing else would. For a deeper look at how physical symptoms factor into PTSD treatment, our blog explores the somatic dimension of trauma recovery.
We also offer SPRAVATO® for patients whose PTSD coexists with treatment-resistant depression. SPRAVATO® is our primary recommended option for patients who meet TRD criteria — it is FDA-approved for treatment-resistant depression, covered by most major insurance plans for eligible patients, and a distinct drug from IV ketamine. When a patient carries both diagnoses, SPRAVATO® may be an appropriate component of care for the depressive dimension, alongside KAP work that addresses the trauma dimension. Discuss with your provider whether your diagnostic profile makes SPRAVATO® a relevant option alongside ketamine therapy and psychotherapy.
Integration: Where the Work Continues
Integration is the work that makes the pharmacological session useful over time. Insights, emotional releases, somatic shifts, and reframings that emerge during a ketamine session do not automatically translate into behavioral change or lasting symptom relief. Our integration therapists work with patients after each session to process what arose, connect it to the patient’s history and goals, and develop practical anchors for the new perspectives or felt senses that emerged. For PTSD patients especially, integration is where the trauma narrative begins to reorganize — where the memory that once hijacked the nervous system gradually becomes something the patient can hold rather than something that holds them. Our PTSD treatment in Minneapolis is built around this full-cycle model of preparation, infusion, and integration.
Frequently Asked Questions
Is ketamine therapy approved for PTSD? No. The use of IV ketamine for PTSD is off-label and not FDA-approved for this indication. The research base is growing and includes studies specifically in treatment-resistant PTSD populations, but it has not reached the level required for FDA approval. We explain this clearly during intake. Results vary by individual; discuss with your provider whether the evidence level and off-label status are factors in your decision.
Will ketamine retraumatize me? With adequate preparation and skilled clinical support, retraumatization is not the typical outcome of KAP for trauma survivors. Our preparation protocol builds safety, establishes grounding tools, and ensures a strong therapeutic relationship before any pharmacological session. We do not rush this phase. That said, difficult material can surface, and our team is trained to work with it therapeutically rather than let it become overwhelming.
How does PTSD treatment with ketamine differ from treating depression? The pharmacological mechanism — NMDA receptor blockade, synaptogenesis, BDNF elevation — is similar. What differs is the psychological context and the centrality of trauma processing. PTSD treatment with ketamine requires a higher degree of trauma-specific preparation and integration work, and the clinical team needs to be specifically trained in trauma-informed care. Our therapists hold trauma-specific certifications that address these requirements.
Can veterans use ketamine therapy for PTSD? Yes, and our institute holds a VA Community Care Network (VCA) contract specifically for this purpose. The VA will refer eligible veterans to us and cover the cost of ketamine infusions through that contract. Veterans should discuss the referral process with their VA care coordinator. We are familiar with the clinical presentations common to military trauma and are prepared to receive VA referrals directly.
What role does SPRAVATO® play in PTSD treatment? SPRAVATO® is FDA-approved for treatment-resistant depression, not PTSD. If a patient carries both treatment-resistant depression and PTSD, SPRAVATO® may be clinically appropriate for the depressive dimension of their care — and as our primary recommended option for TRD, it is covered by most major insurance plans for eligible patients. Discuss with your provider whether your diagnostic profile makes SPRAVATO® a relevant option alongside ketamine therapy and psychotherapy.
Key Takeaways
- PTSD involves dysregulation of fear memory systems in the amygdala, hippocampus, and prefrontal cortex; ketamine may support fear memory reconsolidation during the neuroplastic window
- IV ketamine for PTSD is off-label and not FDA-approved; the evidence base is growing but remains at earlier stages than the depression literature
- Our institute holds a VA Community Care Network (VCA) contract — the VA will refer eligible veterans and cover the cost of ketamine infusions through that pathway
- For patients with comorbid treatment-resistant depression, SPRAVATO® is our primary recommended option — FDA-approved and covered by most major insurance plans for eligible patients
- Preparation and integration are not supplemental — they are essential components of safe, effective PTSD treatment with ketamine
- Results vary by individual; discuss your full trauma history and prior treatments with your provider before beginning
PTSD is a deeply serious condition, and treating it requires more than a drug and a room. At Minnesota Ketamine & Wellness Institute, we bring together the pharmacological precision of certified nurse anesthetist care, the therapeutic depth of trauma-specialized clinicians, and the structural support of preparation and integration to provide the kind of program that genuinely takes trauma seriously. If you or someone you care for has not responded to standard PTSD treatments, we invite you to schedule a consultation and explore what our institute could offer.
References
National Center for PTSD — https://www.ptsd.va.gov/
American Psychiatric Association — https://www.psychiatry.org/patients-families/ptsd/what-is-ptsd
American Society of Ketamine Physicians, Psychotherapists & Practitioners — https://www.askp3.org/
National Institute of Mental Health — https://www.nimh.nih.gov/health/topics/post-traumatic-stress-disorder-ptsd
About Christy Hatcher, MSN, APRN, CRNA
Christy Hatcher, MSN, APRN, CRNA is the owner and lead provider at Minnesota Ketamine & Wellness Institute. She specializes in ketamine infusions as an alternative or adjunct treatment for depression, anxiety, PTSD, and suicidal ideation. The Institute offers a multidisciplinary team with over 40 years of combined experience in mental health and anesthesia services, including therapists who are Certified Clinical Trauma Professionals, Somatic Psychedelic Facilitators, and licensed clinical social workers certified in psychedelic-assisted therapy. The clinic integrates ketamine-assisted psychotherapy (KAP) and integration therapy alongside infusion services, holds a VA Community Care Network (VCA) contract for eligible veterans, and offers SPRAVATO® as its primary FDA-approved, insurance-covered option for treatment-resistant depression.
Medical Disclaimer
The content of this article is provided by Minnesota Ketamine & Wellness Institute for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Ketamine’s use for PTSD is off-label and not FDA-approved for this indication. Individual results vary. Always discuss treatment options, risks, and benefits with a qualified healthcare provider before making any medical decisions.